
    
      To evaluate the preference of subjects for Minirin® oral lyophilisate treatment compared with
      Minirin® tablet treatment after 6 weeks.

      To compare efficacy of the 2 formulations at the end of the 6-week treatment period using
      diary card data.

      To compare ease of use of both formulations at 3 and 6 weeks using a VAS-scale. To validate a
      PNE Quality of Life (QoL) questionnaire. To evaluate safety. To compare compliance with the 2
      formulations
    
  